Bintrafusp Alfa, an Anti-PD-L1:TGFβ Trap Fusion Protein, in Patients with ctDNA-positive, Liver-limited Metastatic Colorectal Cancer

por Morris, Van K., Overman, Michael J., Lam, Michael, Parseghian, Christine M., Johnson, Benny, Dasari, Arvind, Raghav, Kanwal, Kee, Bryan K., Huey, Ryan, Wolff, Robert A., Shen, John Paul, Li, June, Zorrilla, Isabel, Tzeng, Ching-Wei D., Tran Cao, Hop S., Chun, Yun Shin, Newhook, Timothy E., Vauthey, Nicolas, Duose, Dzifa, Luthra, Raja, Haymaker, Cara, Kopetz, Scott
Publicado 2022

KRAS Amplification in Metastatic Colon Cancer is Associated with a History of Inflammatory Bowel Disease and May Confer Resistance to anti-EGFR Therapy

por Favazza, Laura A., Parseghian, Christine M., Kaya, Cihan, Nikiforova, Marina N., Roy, Somak, Wald, Abigail I., Landau, Michael S., Proksell, Siobhan S., Dueker, Jeffrey M., Johnston, Elyse R., Brand, Randall E., Bahary, Nathan, Gorantla, Vikram C., Rhee, John C., Pingpank, James F., Choudry, Haroon A., Lee, Kenneth, Paniccia, Alessandro, Ongchin, Melanie C., Zureikat, Amer H., Bartlett, David L., Singhi, Aatur D.
Publicado 2020

Phase II study of durvalumab (anti-PD-L1) and trametinib (MEKi) in microsatellite stable (MSS) metastatic colorectal cancer (mCRC)

por Johnson, Benny, Haymaker, Cara L, Parra, Edwin R, Soto, Luisa Maren Solis, Wang, Xuemei, Thomas, Jane V, Dasari, Arvind, Morris, Van K, Raghav, Kanwal, Vilar, Eduardo, Kee, Bryan K, Eng, Cathy, Parseghian, Christine M, Wolff, Robert A, Lee, Younghee, Lorenzini, Daniele, Laberiano-Fernandez, Caddie, Verma, Anuj, Lang, Wenhua, Wistuba, Ignacio I, Futreal, Andrew, Kopetz, Scott, Overman, Michael J
Publicado 2022